https://wingibbons.com/2019/04/17/business-development-compass/2019-04-19T22:41:43+00:00monthlyhttps://wingibbons.com/2013/09/24/a-practical-and-direct-strategic-new-product-screening-and-assessment-framework-for-medical-products/https://wingibbons.com/wp-content/uploads/2013/09/slide12.pngPractical Direct and Strategic New Product Screening Framework2019-04-19T22:40:44+00:00monthlyhttps://wingibbons.com/2019/04/17/approach-to-product-market-triangulation/2019-04-19T22:40:08+00:00monthlyhttps://wingibbons.com/2019/04/17/performing-marketing-assessments-for-medical-products/2019-04-19T22:39:08+00:00monthlyhttps://wingibbons.com/professional-history/2019-04-17T20:08:47+00:00weekly0.6https://wingibbons.com/infographics/https://wingibbons.com/wp-content/uploads/2013/11/slide12.pngCardiac Biomarkers and Lab Serviceshttps://wingibbons.com/wp-content/uploads/2013/10/slide111.pngIn-vitro Diagnostic Opportunities for Immunologyhttps://wingibbons.com/wp-content/uploads/2013/10/slide110.pngSlide1https://wingibbons.com/wp-content/uploads/2013/10/slide19.pngSlide1https://wingibbons.com/wp-content/uploads/2013/10/slide18.pngBiomarker Discovery and Validationhttps://wingibbons.com/wp-content/uploads/2013/10/slide17.pngSlide1https://wingibbons.com/wp-content/uploads/2013/10/slide16.pngApproach to Product|Market Triangulationhttps://wingibbons.com/wp-content/uploads/2013/10/slide15.pngSlide1https://wingibbons.com/wp-content/uploads/2013/10/slide12.pngProduct | Market Triangulation - Infographichttps://wingibbons.com/wp-content/uploads/2013/10/slide11.pngSlide12019-04-17T20:06:55+00:00weekly0.6https://wingibbons.com/2013/10/01/a-myth-about-roc-curves-and-c-statistics/https://wingibbons.com/wp-content/uploads/2013/09/slide2.pngSlide2https://wingibbons.com/wp-content/uploads/2013/09/slide14.pngSlide12019-01-22T21:06:25+00:00monthlyhttps://wingibbons.com/2017/07/12/perspectives-update/2017-07-12T16:05:51+00:00monthlyhttps://wingibbons.com/2013/09/26/co-optimizing-commercial-planning-and-product-development-with-orthogonal-market-segments/https://wingibbons.com/wp-content/uploads/2013/09/figure-a.pngFigure Ahttps://wingibbons.com/wp-content/uploads/2013/09/figure-b.pngFigure Bhttps://wingibbons.com/wp-content/uploads/2013/09/figurec.pngFigureC2016-12-29T03:11:38+00:00monthlyhttps://wingibbons.com/2013/11/18/another-oft-forgotten-not-so-subtlety-of-roc-aucs-c-statistics/https://wingibbons.com/wp-content/uploads/2013/11/slide11.pngSlide12016-12-09T21:19:24+00:00monthlyhttps://wingibbons.com/2016/10/11/barriers-to-personalized-medicine-and-companion-diagnostics/https://wingibbons.com/wp-content/uploads/2016/10/companion-diagnostic-101016.pngcompanion-diagnostic-1010162016-10-11T17:39:07+00:00monthlyhttps://wingibbons.com/2013/10/21/detailed-perspectives-on-biomarker-discovery-and-development/https://wingibbons.com/wp-content/uploads/2013/10/slide06.pngSlide06https://wingibbons.com/wp-content/uploads/2013/10/slide05.pngBig Four Biaseshttps://wingibbons.com/wp-content/uploads/2013/10/slide04.pngSlide04https://wingibbons.com/wp-content/uploads/2013/10/slide03.pngSlide032016-10-03T20:10:20+00:00monthlyhttps://wingibbons.com/2014/12/23/selling-a-pre-commercial-diagnostic-or-life-science-company/2016-09-30T21:45:27+00:00monthlyhttps://wingibbons.com/2016/09/05/httpwww-nytimes-com20160827scienceall-donated-blood-in-us-will-be-tested-for-zika-htmlpartnerrssemcrsssmidtw-nythealthsmtypcur_r0/2016-09-28T23:26:10+00:00monthlyhttps://wingibbons.com/brief-survey/2016-09-28T23:19:04+00:00weekly0.6https://wingibbons.com/contact/2016-09-28T22:46:44+00:00weekly0.6https://wingibbons.com/2015/02/17/siloam-biosciences-optimiser-plus-microfluidics-for-life-science-and-diagnostic-assays-just-a-drop-of-blood-for-multiple-tests/2016-09-19T20:46:58+00:00monthlyhttps://wingibbons.com/published-patent-application/2015-01-09T22:06:55+00:00weekly0.6https://wingibbons.com/2014/09/10/siloam-biosciences-receives-a-1-million-phase-ii-sbir-contract-to-develop-an-immunodiagnostic-system-using-only-%c2%bc-of-a-drop-of-blood-for-cancer-tests/2015-01-02T17:24:53+00:00monthlyhttps://wingibbons.com/about/2014-10-08T23:42:58+00:00weekly0.6https://wingibbons.com/scientific-publications/2014-10-08T23:42:42+00:00weekly0.6https://wingibbons.com/2013/09/13/performing-market-assessments-for-medical-diagnostic-products/https://wingibbons.com/wp-content/uploads/2013/09/slide11.pngMarket Research to Assess Medical Products - Phase 1 Process2013-11-22T19:54:57+00:00monthlyhttps://wingibbons.com/2013/11/19/cardiac-biomarkers-and-services/https://wingibbons.com/wp-content/uploads/2013/11/slide10.pngSlide10https://wingibbons.com/wp-content/uploads/2013/11/slide09.pngSlide09https://wingibbons.com/wp-content/uploads/2013/11/slide08.pngSlide08https://wingibbons.com/wp-content/uploads/2013/11/slide07.pngSlide07https://wingibbons.com/wp-content/uploads/2013/11/slide06.pngSlide06https://wingibbons.com/wp-content/uploads/2013/11/slide05.pngSlide05https://wingibbons.com/wp-content/uploads/2013/11/slide04.pngSlide042016-01-29T16:44:58+00:00monthlyhttps://wingibbons.com/2013/11/05/alzheimers-disease-biomarkers-are-in-vitro-diagnostics-really-needed/https://wingibbons.com/wp-content/uploads/2013/11/slide2.pngSlide2https://wingibbons.com/wp-content/uploads/2013/11/slide1.pngSlide12014-02-21T13:34:41+00:00monthlyhttps://wingibbons.com/2013/09/12/execution-framework-for-disease-management-in-medical-products/https://wingibbons.com/wp-content/uploads/2013/09/dis-man-overall-segmentation.pngDIs Man overall segmentation2013-10-24T17:28:52+00:00monthlyhttps://wingibbons.com/2013/09/18/why-its-difficult-to-make-a-bd-deal-with-an-established-company-and-how-to-solve-this/2013-10-18T22:32:31+00:00monthlyhttps://wingibbons.com/2013/09/22/evocative-descriptions-of-novel-diagnostic-outputs-and-how-they-might-be-sensibly-chosen/https://wingibbons.com/wp-content/uploads/2013/09/figure-1.pngFigure 1https://wingibbons.com/wp-content/uploads/2013/09/figure-2.pngFigure 2https://wingibbons.com/wp-content/uploads/2013/09/figure-3.pngFigure 32013-10-16T05:28:24+00:00monthlyhttps://wingibbons.com/2013/09/10/useful-demographics-to-gather-in-medical-product-surveys-2/https://wingibbons.com/wp-content/uploads/2013/10/slide14.pngSlide12013-10-10T15:24:55+00:00monthlyhttps://wingibbons.com/2013/09/11/extracting-clinical-value-from-next-gen-sequencing/https://wingibbons.com/wp-content/uploads/2013/09/slide1.pngSlide1Market Research to Assess Medical Products - Phase 2 Processhttps://wingibbons.com/wp-content/uploads/2013/09/next-gen-sequencing-translation-to-clinic-infographic.pngNext Gen Sequencing Translation to Clinic - Infographic2013-10-09T15:18:44+00:00monthlyhttps://wingibbons.com/2013/10/08/product-market-triangulation/https://wingibbons.com/wp-content/uploads/2013/10/slide5.pngSlide5https://wingibbons.com/wp-content/uploads/2013/10/slide4.pngSlide4https://wingibbons.com/wp-content/uploads/2013/10/slide3.pngSlide3https://wingibbons.com/wp-content/uploads/2013/10/slide2.pngSlide2https://wingibbons.com/wp-content/uploads/2013/10/slide13.pngSlide12013-10-08T16:37:45+00:00monthlyhttps://wingibbons.com/2013/09/20/heart-failure-large-market-opportunities-for-new-biomarkers/https://wingibbons.com/wp-content/uploads/2013/09/slide08.pngSlide082013-09-30T20:57:04+00:00monthlyhttps://wingibbons.com/2013/09/10/opportunities-for-new-testing-to-screen-blood-donations/https://wingibbons.com/wp-content/uploads/2013/09/slide15.pngSlide12013-09-30T20:48:51+00:00monthlyhttps://wingibbons.com/2013/09/16/process-to-divest-therapeutic-pipelines/https://wingibbons.com/wp-content/uploads/2013/09/implementation-actions.pngImplementation Actions2013-09-30T16:58:31+00:00monthlyhttps://wingibbons.com/2013/09/10/five-step-approach-for-product-assessment-and-analytical-modeling/2013-09-13T19:17:49+00:00monthlyhttps://wingibbons.comdaily1.02019-04-19T22:41:43+00:00